A recent analysis reveals that the mRNA vaccine mRNA-1273 is more effective than the protein-based vaccine NVX-CoV2705 in preventing severe forms of COVID-19. This study covers more than one million insured American adults, vaccinated between August 2024 and February 2025, a period marked by the circulation of new virus variants.<\/p>\n
The vaccines used during this season differed not only in their technology but also in the targeted strains. The mRNA-1273 targeted the KP.2 variant, while NVX-CoV2705 targeted the JN.1 variant. Researchers compared their effectiveness by following participants for up to six months after vaccination.<\/p>\n
The results show that the mRNA vaccine reduces the risk of medically managed COVID-19 cases by 32% compared to the protein-based vaccine. For COVID-19-related hospitalizations, the reduction reaches 41%. Among people aged 65 and older, who are often more vulnerable, the mRNA vaccine decreases medically managed cases by 26% and hospitalizations by 42%.<\/p>\n
mRNA vaccines work by delivering a genetic message to cells, which then produce a harmless viral protein. This triggers an immune response. Protein-based vaccines, on the other hand, directly contain the viral protein, manufactured in a laboratory, which stimulates the immune system. Both approaches are designed to prepare the body to recognize and fight the virus in case of infection.<\/p>\n
The study suggests that the difference in effectiveness could be explained by two factors. First, mRNA vaccines appear to provoke a stronger immune response, particularly by stimulating T cells more, which are essential for lasting protection. Second, the targeted variant plays a role. The mRNA-1273, adapted to the KP.2 variant, may offer better coverage against the strains circulating during the study period, such as KP.3 or XEC, which emerged after JN.1.<\/p>\n
The cumulative risk curves show that the additional protection provided by the mRNA vaccine appears quickly after injection and is maintained without diminishing throughout the follow-up period. This indicates prolonged effectiveness, crucial for enduring an entire respiratory season.<\/p>\n
This research highlights the importance of choosing vaccines adapted to dominant variants and considering the technology used. mRNA vaccines, due to their flexibility, allow for faster updates to their composition to keep pace with the virus’s evolution. This could partly explain their better performance in a context where the virus frequently mutates.<\/p>\n
Study participants were predominantly aged 65 or older, with a balanced distribution between men and women. Many had medical conditions increasing the risk of severe disease, such as heart disease, diabetes, or immunosuppression. Despite these risk factors, the mRNA vaccine demonstrated consistent superiority.<\/p>\n
These findings reinforce the idea that the choice of vaccine, both in terms of technological platform and targeted strain, has a significant impact on the protection offered. They could guide decisions by health authorities and clinicians for future vaccination campaigns, especially in a context where the virus continues to circulate and evolve.<\/p>\n
DOI:<\/strong> https:\/\/doi.org\/10.1007\/s12325-026-03650-z<\/a><\/p>\n Title:<\/strong> Comparative Effectiveness of mRNA-1273 Versus Protein-Based NVX-CoV2705 Vaccination on COVID-19-Related Outcomes Among Insured Adults in the United States During 2024\u20132025: A Retrospective Matched Cohort Study<\/p>\n Journal:<\/strong> Advances in Therapy<\/p>\n Publisher:<\/strong> Springer Science and Business Media LLC<\/p>\n Authors:<\/strong> Amanda Wilson; Ekkehard Beck; Heather Hensler; Nevena Vicic; Keya Joshi; Emily Patry; Linwei Li; Jane Wang; Chris Clarke<\/p>\n","protected":false},"excerpt":{"rendered":" mRNA vaccine offers better protection against COVID-19 than protein-based vaccine A recent analysis reveals that the mRNA vaccine mRNA-1273 is more effective than the protein-based vaccine NVX-CoV2705 in preventing severe forms of COVID-19. This study covers more than one million insured American adults, vaccinated between August 2024 and February 2025, a period marked by the… Continue reading mRNA vaccine offers better protection against COVID-19 than protein-based vaccine<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-51","post","type-post","status-publish","format-standard","hentry","category-health","entry"],"_links":{"self":[{"href":"https:\/\/thepublichealthreview.com\/en\/wp-json\/wp\/v2\/posts\/51","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thepublichealthreview.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thepublichealthreview.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thepublichealthreview.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thepublichealthreview.com\/en\/wp-json\/wp\/v2\/comments?post=51"}],"version-history":[{"count":1,"href":"https:\/\/thepublichealthreview.com\/en\/wp-json\/wp\/v2\/posts\/51\/revisions"}],"predecessor-version":[{"id":52,"href":"https:\/\/thepublichealthreview.com\/en\/wp-json\/wp\/v2\/posts\/51\/revisions\/52"}],"wp:attachment":[{"href":"https:\/\/thepublichealthreview.com\/en\/wp-json\/wp\/v2\/media?parent=51"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thepublichealthreview.com\/en\/wp-json\/wp\/v2\/categories?post=51"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thepublichealthreview.com\/en\/wp-json\/wp\/v2\/tags?post=51"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}